As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
|Articles|December 1, 2012
- Pharmaceutical Executive-12-01-2012
- Volume 0
- Issue 0
Top Medical Innovations for 2013
Author(s)Ben Comer
Ben Comer profiles 10 innovative technologies designated as new and revolutionary tools for the treatment of disease and disability.
Advertisement
At the conclusion of the Cleveland Clinic's Medical Innovations Summit each year, 10 innovative technologies are unveiled before the audience, and designated as new and revolutionary tools for the treatment of disease and disability. Selections for the Top 10 are chosen by way of a process that includes personal interviews with over 100 senior Cleveland Clinic physicians. Here are a few of the technologies that made the cut for 2013.
Articles in this issue
almost 14 years ago
Pharmaceutical Executive Digital Edition - December 2012almost 14 years ago
Obamacare, Innovation and Pricingalmost 14 years ago
Germany's Price Reform Revolutionalmost 14 years ago
Transforming Drug Development: A Lilly–Covance Case Studyalmost 14 years ago
The Puzzle Master: EMA's Guido RasiAdvertisement
Related to this article
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
3
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
4
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
5